Your browser doesn't support javascript.
loading
Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation.
Yeh, Albert C; Koyama, Motoko; Waltner, Olivia G; Minnie, Simone A; Boiko, Julie R; Shabaneh, Tamer B; Takahashi, Shuichiro; Zhang, Ping; Ensbey, Kathleen S; Schmidt, Christine R; Legg, Samuel R W; Sekiguchi, Tomoko; Nelson, Ethan; Bhise, Shruti S; Stevens, Andrew R; Goodpaster, Tracy; Chakka, Saranya; Furlan, Scott N; Markey, Kate A; Bleakley, Marie E; Elson, Charles O; Bradley, Philip H; Hill, Geoffrey R.
Affiliation
  • Yeh AC; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: ayeh@fredhutch.org.
  • Koyama M; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Waltner OG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Minnie SA; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Boiko JR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Shabaneh TB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Takahashi S; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Zhang P; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Ensbey KS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Schmidt CR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Legg SRW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Sekiguchi T; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Nelson E; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Bhise SS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Stevens AR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Goodpaster T; Experimental Histopathology Core, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Chakka S; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Furlan SN; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Markey KA; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Bleakley ME; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Elson CO; Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
  • Bradley PH; Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Hill GR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: grhill@fredhutch.org.
Immunity ; 57(7): 1648-1664.e9, 2024 Jul 09.
Article in En | MEDLINE | ID: mdl-38876098
ABSTRACT
Allogeneic T cell expansion is the primary determinant of graft-versus-host disease (GVHD), and current dogma dictates that this is driven by histocompatibility antigen disparities between donor and recipient. This paradigm represents a closed genetic system within which donorcells interact with peptide-major histocompatibility complexes (MHCs), though clonal interrogation remains challenging due to the sparseness of the T cell repertoire. We developed a Bayesian model using donor and recipient T cell receptor (TCR) frequencies in murine stem cell transplant systems to define limited common expansion of T cell clones across genetically identical donor-recipient pairs. A subset of donor CD4+ T cell clonotypes differentially expanded in identical recipients and were microbiota dependent. Microbiota-specific T cells augmented GVHD lethality and could target microbial antigens presented by gastrointestinal epithelium during an alloreactive response. The microbiota serves as a source of cognate antigens that contribute to clonotypic T cell expansion and the induction of GVHD independent of donor-recipient genetics.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graft vs Host Disease Limits: Animals Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graft vs Host Disease Limits: Animals Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article